News
Texas sues, accusing Eli Lilly of 'bribing' physicians to prescribe Zepbound, Mounjaro and other drugs
Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as administrative support services that helped providers process insurance claims.
Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...
2don MSN
Why Eli Lilly Stock Popped Today
Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.
In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...
Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback